Cohen JM, et al. – In this study, the physicians sought to assess the efficacy and safety of fremanezumab as an add–on preventive therapy in individuals with episodic migraine (EM) and chronic migraine (CM) who were on stable doses of preventive migraine medications. They recommended fremanezumab as a safe and effective add–on treatment for migraine patients who were concomitantly treated with other migraine preventive medications.

• The physicians performed 2 randomized placebo-controlled studies tested once-monthly subcutaneous injections of various dosing regimens of fremanezumab vs. placebo in EM and CM.
• They captured headache information daily using an electronic headache diary.
• They pooled data from patients who were on stable preventive medications and taking fremanezumab doses of 225 mg or 675/225 mg, or placebo for these post hoc analyses.

• The study sample consisted of 133 patients, (67 fremanezumab and 66 placebo).
• For fremanezumab, total reduction in migraine days for the duration of the study was 12.4 and 7.4 for placebo (P = .0321).
• Also, there were reduction in moderate/severe headache days (12.5 vs 7.1, P = .0058), and days using acute medication for headaches relative to placebo (11.6 vs 7.5, P = .0414).
• Treatment emergent adverse events were generally mild and transient.
• No serious adverse events were considered to be treatment-related by the site investigators.